Literature DB >> 10552961

Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.

B Falini1, K Pulford, A Pucciarini, A Carbone, C De Wolf-Peeters, J Cordell, M Fizzotti, A Santucci, P G Pelicci, S Pileri, E Campo, G Ott, G Delsol, D Y Mason.   

Abstract

The tumor cells in ALK-positive lymphoma ("ALKoma") usually express the product of the NPM-ALK chimeric gene, generated by the t(2;5) chromosomal translocation. However, 10% to 20% of ALK-positive lymphomas express ALK fusion protein(s) other than NPM-ALK, and in this report, we describe the immunohistologic and clinicopathologic features of 15 such cases. The absence of the NPM-ALK fusion gene was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) in 8 cases and by fluorescence in situ hybridization (FISH) analysis in a further 2 cases. In each case, ALK staining was restricted to the cytoplasm and the N-terminus of NPM to the nucleus (contrasting with lymphomas expressing NPM-ALK in which cytoplasmic as well as nuclear labeling is seen). However, in the course of screening 53 ALK-positive lymphomas, 2 biopsies were found that had a "cytoplasm-only" ALK staining pattern but that nevertheless were shown to carry the (2;5) (by NPM staining and RT-PCR). The 15 cases resembled typical NPM-ALK-positive lymphomas in that all were of T or null phenotype, usually occurred in young male patients, and frequently presented with advanced disease associated with systemic symptoms and extranodal involvement. Moreover, their prognosis was excellent and indistinguishable from that of classical t(2;5)-positive tumors, but was clearly different from that of ALK-negative anaplastic large-cell lymphomas. These results suggest that lymphomas carrying variants of the NPM-ALK fusion protein can be detected by immunostaining for ALK and NPM and also that they can be grouped with classical t(2;5)-positive tumors as a single entity (ALK-positive lymphoma or "ALKoma") that shows a better prognosis than ALK-negative anaplastic large-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552961

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Molecular diagnostic approach to non-Hodgkin's lymphoma.

Authors:  D A Arber
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

2.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 3.  Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation.

Authors:  Sheila Weitzman; Kaveri Suryanarayan; Howard J Weinstein
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

4.  5'-(RACE) identification of rare ALK fusion partner in anaplastic large cell lymphoma.

Authors:  N Scott Reading; Stephen D Jenson; Jeffrey K Smith; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

5.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 6.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

Review 7.  ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Authors:  Kana Sakamoto; Hideki Nakasone; Yuki Togashi; Seiji Sakata; Naoko Tsuyama; Satoko Baba; Akito Dobashi; Reimi Asaka; Chien-Chen Tsai; Shih-Sung Chuang; Koji Izutsu; Yoshinobu Kanda; Kengo Takeuchi
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

Review 8.  Primary anaplastic large cell lymphoma of the testis.

Authors:  J Azúa-Romeo; R Alvarez-Alegret; P Serrano; E Mayayo
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

9.  Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses.

Authors:  José Ignacio Martín-Subero; Ilse Chudoba; Lana Harder; Stefan Gesk; Werner Grote; Francisco Javier Novo; María José Calasanz; Reiner Siebert
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

Authors:  Maria Paola Martelli; Gabriella Sozzi; Luis Hernandez; Valentina Pettirossi; Alba Navarro; Davide Conte; Patrizia Gasparini; Federica Perrone; Piergiorgio Modena; Ugo Pastorino; Antonino Carbone; Alessandra Fabbri; Angelo Sidoni; Shigeo Nakamura; Marcello Gambacorta; Pedro Luis Fernández; Jose Ramirez; John K C Chan; Walter Franco Grigioni; Elias Campo; Stefano A Pileri; Brunangelo Falini
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.